Regarding the utilization of immunotherapies to treat NM due to melanoma, two separate cohort studies have demonstrated the use of IT interleukin-2 (IL-2) with varying chemotherapy combinations and reported a similar survival of 7.8–7.9 months, respectively. Here, IL2 is linked to nemaline myopathy.